• Artiva Biotherapeutics highlighted updated Phase 2a data for AlloNK (AB-101) with rituximab in Sjögren disease at ISSjD 2026.
• Results were presented in an oral session, covering patients with at least six months of follow-up as of the July 2, 2026 cutoff.
• Trial readout showed clinically meaningful improvements in disease activity, patient-reported symptoms, and salivary function at six months.
• Expanded safety update across 73 Phase 2a patients supported an outpatient approach, with no discontinuations tied to adverse events.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artiva Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010730PRIMZONEFULLFEED9837304) on October 01, 2026, and is solely responsible for the information contained therein.